■ 학력 및 경력

1993 의학학사 전남대학교 의과대학 

2003 의학박사 전남대학교 의과대학원 

1993 – 1998 전남대병원 진단검사의학과 인턴 및 전공의 

2003 – 2015전남대병원 및 전남대병원 전임강사,조교수, 부교수 

2007 – 2009 St Jude Children Research Hospital(미국)“NK cell cancer immunotherapy”로 연수 

2015 – 현재 삼성서울병원 교수, 성균관의대 교수 / 삼성융합의과학원 융합의과학과, 의료기기산업학과 참여교원 

■ 연구분야 키워드 NK cells, Chimeric Antigen receptor (CAR), CAR-NK cells, Cancer, immunotherapy 

■ 대표 업적(최근 3년간, 책임저자) 

1) Integrative Magneto-Microfluidic Separation of Immune Cells Facilitates Clinical Functional Assays. Small. 2023 Jun 27:e2302809. (한빛사 Cell Biology 영역에 소개됨) 

2) Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells. Sci Rep. 2023 Jun 11;13(1):9493 

3) Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model. Cancer Immunol Immunother. 2023 May;72(5):1233-1246 

4) Selective Expansion of NKG2C+ Adaptive NK Cells Using K562 Cells Expressing HLA-E. Int J Mol Sci. 2022 Aug 20;23(16):9426. 

5) Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used. Ann Lab Med. 2022 Nov 1;42(6):638-649 

6) Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma. Ann Lab Med. 2022 Sep 1;42(5):558-565. 

7) Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21. Cancer Immunol Immunother. 2021 Jul 20 

8) Expanded natural killer cells augment anti-myeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol. 2021 May 12. doi: 10.1038/s41423-021-00686-9. (한빛사 Cell Biology 영역에 소개됨)